LILRB2 (ILT4) Program
Solid Tumors (likely)
Preclinical or Early ClinicalActive
Key Facts
Indication
Solid Tumors (likely)
Phase
Preclinical or Early Clinical
Status
Active
Company
About Immune-Onc Therapeutics
Immune-Onc Therapeutics is a private, clinical-stage biotech company pioneering a new class of immunotherapies targeting myeloid cell inhibitory receptors. Founded in 2016 and based in Palo Alto, California, the company is advancing a pipeline of first-in-class antibodies, with its lead asset IO-202 in Phase 1b expansion for blood cancers like AML and CMML. Immune-Onc's strategy is built on the premise that modulating myeloid cells, a key component of the innate immune system, can unlock therapeutic benefits for patients unresponsive to existing checkpoint inhibitors, addressing significant unmet needs in both oncology and autoimmunity.
View full company profile